As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India.[9] The company derived 97% of its operating revenue from the Indian market,[10] where it is reportedly the fourth largest pharmaceutical company by domestic sales.[9] Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce incondoms,[11] Prega News inpregnancy test kits,[12] and Unwanted-72 inemergency contraception.[13]
Mankind Pharma was incorporated in 1991, and actively started its operations in 1995, with the contributions of two brothers,Ramesh C. Juneja and Rajeev Juneja, who established the company with a seed capital of₹5,000,000.[14][15] The company was started with 20 employees and launched in two states in the first year of its operation.[16][17]
Mankind Pharma initially targeted price-sensitive drugs, with a focus on rural market;[18] its early products included antibacterial drug Zenflox and prescription antibiotic Moxikind CV, which were priced at a steep discount to the existing products in the market.[19] The company ventured into theover-the-counter segment in 2007, focusing primarily on sexual healthcare products.[20][21]
The company acquired Magnet Labs Pvt. Ltd. to enter the antipsychotic segment in 2007.[22] It acquired Longifene-an appetite stimulant for children in January 2010 which was earlier a brand ofUCB.[23]
In 2017, Mankind Pharma established Pathkind Labs, a provider of diagnostics and healthcare tests.[24]
In 2019, Mankind became the first Indian company and second only in the world to develop and launchDydrogesterone, a drug used in high-risk pregnancies and infertility by the brand name Dydroboon.[25]
In 2022, Mankind acquiredPanacea Biotec Pharma's domestic formulations brands in India and Nepal for₹1,872 crore (US$220 million).[26] It then acquired a respiratory treatment product, and an infant skincare brand fromDr. Reddy's Laboratories.[27] It also bought a majority stake in theAyurvedic and herbal products manufacturer, Upakarma Ayurveda.[28]
In April 2023, Mankind Pharma launched itsinitial public offering (IPO), with existing investors selling₹4,326 crore (US$510 million) worth of shares.[31]
In 2024, Mankind Pharma acquired a 100% stake in Bharat Serums and Vaccines (BSV) from private equity firmAdvent International for an enterprise value of₹13,630 crore (US$1.6 billion).[32] The deal included over 2,500 employees joining the company. Mankind also aimed to raise up to ₹10,000 crore through non-convertibledebentures to support its growth initiatives.[32]
₹12,207 crore (US$1.4 billion) (2025)
.jpg)